Serum Institute partners with Oxford University to combat Meningitis-B
What's the story
The Serum Institute of India has entered into a five-year licensing deal with the University of Oxford, according to a press release on Tuesday (April 16).
This partnership aims to produce and distribute a vaccine specifically designed to combat Meningitis-B, a lethal infection affecting the brain and spinal cord.
The collaboration signifies an important step toward global health improvement.
Vaccine accessibility
CEO highlights importance of affordable vaccines
Serum Institute's CEO, Adar Poonawalla, emphasized the crucial role of affordable vaccines in disease prevention during the announcement.
He stated that this partnership "exemplifies a shared dedication to global health and underscores the importance of accessible vaccines."
Poonawalla also noted that this alliance marks a significant advancement in the fight against Meningitis, aiming to provide life-saving protection to those most vulnerable.
Expansion goals
Serum Institute's global recognition and future plans
The World Health Organization pre-qualified Serum Institute's MenFive vaccine in July 2023, bolstering the company's role in managing global Meningitis outbreaks.
This recognition has further solidified the firm's position as a key player in the healthcare sector.
In addition to this, the Serum Institute plans to extend its market reach by offering vaccines to international travelers.
Academic partnership
Oxford University's commitment to vaccine innovation
Simon Warner, Head of Licensing & Ventures - Life Sciences at Oxford University Innovation, praised the deal as a testament to Oxford's dedication to vaccine innovation.
He emphasized the university's commitment to creating effective vaccines, and highlighted the crucial role of academic licensing as well as successful commercial partnerships, in addressing global health issues.